BrightSpring Health Services, Inc. Common Stock Wells Fargo 21st Annual Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
- BrightSpring reported a significant acceleration in pharmacy segment EBITDA growth, reaching nearly 40% in 2025 and over 40% in the first half of 2026, compared to a 6-8% range in prior years.
- Growth drivers in the pharmacy segment include specialty pharmacy LDD wins and ramp-ups, generic conversions, fee-for-service infusion business growth, and operational efficiencies including AI and automation.
- Gross profit per prescription showed seasonality effects with Q1 benefiting from price appreciation related to inventory; underlying gross profit per script grew from Q1 to Q2 when excluding this effect.
- The company highlighted a shift toward exclusive and ultra-narrow specialty pharmacy arrangements, especially for oncology and rare/orphan drugs, emphasizing high-quality service and patient adherence.
- LDD ramp-up typically takes two to three years, with good visibility on portfolio wins 12 to 18 months ahead, supporting recent financial targets.
- Infusion market growth is a strategic focus, targeting density expansion in acute and chronic specialty infusion with tailored sales strategies.
- Generic conversions involve preparing volume in advance and rapid execution at launch, with nearly 100% conversion achieved quickly; patient satisfaction and adherence support volume retention post-conversion.
- Generic pricing typically steps down over 5-10 years, but volume growth and new LDDs offset this headwind.
- Key 2026 generic launches include Pomalyst, Busalyf, and Rydap, with Pomalyst largely run rated in Q1; generic conversions create new market opportunities expanding the patient base.
- 2027 generic conversions are expected later in the year with more impact in 2028; these conversions remain important to the ecosystem.
- IRA drug price negotiations had the largest impact in 2026, with 2027 impact expected to be about half; the company has negotiated offsets and enhanced dispensing fees to mitigate impacts.
- Operating expenses increased due to permanent investments like Salesforce expansion and temporary investments such as IT systems and AI initiatives, aimed at driving future growth.
- Provider business EBITDA grew nearly 20% organically in the recent quarter, driven by volume growth, acquisition integration (e.g., MEDICIS, LHC), and workforce stability despite wage investments.
- Over 80 acquisitions have been completed with all but two exceeding initial EBITDA targets; pro forma multiples are under four times with operational and revenue synergies realized.
- AI initiatives focus on automating manual, high-touch processes such as rapid referral intake in infusion and revenue cycle improvements, with a 30-person team developing use cases.
- Balance sheet leverage is approaching two times, with a mid-twos target; management prioritizes highly accretive M&A while maintaining disciplined deal pricing and strategic fit.
- The company aims to keep share count flat and may consider capital returns including buybacks in 9-12 months, depending on deal flow and cash generation.
- M&A focus remains on small tuck-in deals under $5 million EBITDA and some deals in the $10-15 million EBITDA range, with occasional larger deals up to $50 million EBITDA possible.
- Integration capabilities are strong with a dedicated integration management office and playbook, supporting growth in pharmacy infusion, home and community pharmacy, and provider services.
- Cross-selling and integration initiatives include providing pharmacy services to hospice patients and building integrated care teams targeting senior living communities with multiple service lines.
- The company is exploring value creation through ACOs and iSnip programs, leveraging outcomes for differentiated payment models, though these remain smaller parts of the business.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Thank you everyone. We're really pleased to close out the conference. The last fireside chat will be with BrightSpring. BrightSpring is a provider of a variety of pharmacy and provider services from the company. We're happy to have CFO Jennifer Phipps here with us and David Deuchler from Investor Relations. Thanks for being here. Really appreciate you making the time. Any kind of introductory commentary you'd like to make, or should we just get right into a question?
No, we can go ahead and jump right into the questions.
Okay, great. Well, maybe just to step back a little bit, in the pharmacy business, EBITDA growth in this business, if we go back to call it 2022, 2023, 2024, really range in that 6%-8% range. Since that time, you've really seen a remarkable acceleration with EBITDA growing almost 40% in 2025, and you're over 40% in the first half of 2026. From a big picture perspective, I guess, how should we break down the acceleration between the different key components of the business?
Yeah. From an acceleration standpoint, I would say we have a number of growth drivers across our pharmacy segment. First, specialty pharmacy, the growth drivers have been LDD wins. These are not necessarily in any particular order, but LDD wins that we've had in each of the years.
Ramping of prior LDDs that we win in prior years, because those typically take 2, 3, 4 years to ramp fully in the marketplace. We have seen growth drivers in terms of generic conversions, and our fee-for-service business associated with supporting the LDD manufacturers have driven growth in our specialty pharmacy business. From an infusion standpoint, we have continued to see volume growth across acute and targeted chronic infusion underpinned by our high-quality services. From a home and community standpoint, the growth drivers have been multifaceted there as well. We continue to obviously seek profitable volume growth. We did have some script changes as we talked about last year as we exited some uneconomic customers from a profitability standpoint.
Growth in good core volume there, but also a significant amount of operational efficiencies that we have been working on, whether they are driven by AI projects and automation that we have done, as well as other operational efficiencies that we have been working on in that business.
Okay, that is great. Then maybe to zoom in a little bit more so just to come back to the second quarter, I think one thing if we were to look at the pharmacy solutions results, I think gross profit per prescription was a bit lower in the second quarter than it was in the first quarter. I think that was a bit of a point of confusion for the market, given some expectations, for a step up for certain recent generic launches. As you think about going from Q1 to Q2 and the various factors that impacted those comparisons, just help us think about that and when the company discusses that it sees Q2 underlying gross profit is higher than Q1, what are the considerations to keep in mind there?
Yeah. In Q1, we typically have some, and we have this every year, some seasonality for price appreciation that occurs related to inventory that we have on hand. That is a dynamic that benefits the first quarter. When you exclude that benefit, we actually did see growth in a gross profit per script. I think there is a number of drivers. Obviously, gross profit per script is really an output for us of probably 70 to 80 different factors across each of our different business lines, and how our different business lines. So each one of our products and each one of our different business lines has a different GP per script profile.
We're really focused on growing underlying EBITDA GP dollars and EBITDA growth for the sustainable long term. That's really what we're focused on, and we really look at GP per script as an output.
Yeah. We're certainly not going to stop growing, for example, or stop working to grow our home and community pharmacy business because that is our lowest per script, just because that could negatively impact a gross profit per script measure.
Yeah. Again, we're really focused on the total and long-term sustainable growth rate across both of those.
Okay. Then, as you discussed a little bit with one of your previous answers about the acceleration, the track record of winning new LDDs has obviously been phenomenal. When we think about the key considerations that manufacturers have when they're selecting specialty pharmacies, how different are they now than they are in the past? Many of your recent launches have been concentrated in exclusive and ultranarrow arrangements. Do you start to think of this increasingly as being the new normal in many cases?
We continue to see this being the path that oncology and rare and orphan drugs are going into these exclusive and ultranarrow categories as manufacturers and pharma have gotten increasingly comfortable that a small number of pharmacies can fully service their drug. We are focused on having really high-quality services. We have one of the best time to first fills compared to many of our competitors. We are focused on having high patient satisfaction scores, medication possession ratio, which is an adherence measure. We think that produces ultimately better outcomes which is valued by our pharma partners. We seek to just be a full-service partner for any of the needs that pharma would have in servicing their drugs, and we take pride in executing on those.
Okay, that's great. Obviously, you provided some attractive financial targets for the business quite recently. As we think about the role that LDDs play in that, I guess how much of that growth can be delivered on, I guess, from LDDs that you've already won and have a pretty healthy ramp-up period in front of them? I guess how dependent are the targets on winning LDDs that you don't yet have today?
Yeah. Again, typically it takes 2 to 3 years for a drug to fully ramp in the marketplace. We actually have seen growth this year from even a small amount, but from drugs that were launched in 2021.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring